ImageneBio (Nasdaq: IMA) announced that its Board’s Compensation Committee granted inducement equity awards on August 14, 2026 under Nasdaq Listing Rule 5635(c)(4). These include 79,000 RSUs and 56,525 NSOs to three newly hired non‑executive employees and 65,000 RSUs and 56,000 NSOs to Chief Financial Officer Yanina Grant-Huerta, all under the 2025 Equity Inducement Plan. Ms. Grant-Huerta also received 39,000 RSUs under the 2025 Equity Incentive Plan. RSUs vest over four years using annual or 1‑year cliff plus quarterly schedules, while NSOs, priced at $5.84 per share, vest over four years with a 1‑year cliff and monthly vesting thereafter.
Loading...
Loading translation...
Positive
Inducement equity awards to attract and retain four key employees, including CFO
Exercise price set at $5.84 per NSO, aligned with August 14, 2026 closing price
Four-year vesting schedules support employee retention and long-term alignment
Negative
Potential dilution from 183,000 RSUs and 112,525 stock options granted
Ongoing stock-based compensation expense implied by multi-year vesting of RSUs and NSOs
Market Context
An effective S-3 dated August 5 permits up to $200,000,000 and includes a $17,000,000 at-the-market ...
Analysis
An effective S-3 dated August 5 permits up to $200,000,000 and includes a $17,000,000 at-the-market program. Against these equity awards, recent insider activity was Net Selling; financing capacity and ownership activity remain relevant context.
Private placement announcement preceded a 23.42% reaction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Prior news reactions were mostly aligned with the announcement sentiment, although the May 7 earnings update was followed by a -10.49% reaction despite positive financing and program updates.
"granted as inducements material to the new employees entering into employment"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
restricted stock unitsfinancial
"inducement awards consisting of 79,000 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
non-qualified stock optionsfinancial
"and 56,525 non-qualified stock options to three newly hired"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
monoclonal antibodymedical
"a receptor targeting, nondepleting anti-OX40 monoclonal antibody"
A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.
phase 2b clinical trialmedical
"currently conducting a Phase 2b clinical trial of olevaprubart"
A phase 2b clinical trial is a mid-stage medical study that tests whether a new treatment works and which dose is best by enrolling a larger group of patients than earlier phase 2 studies. For investors, its results are a key signal of a drug’s real-world effectiveness and safety, and can strongly influence the chances of later regulatory approval, future funding needs, and a company’s stock outlook—like a larger pilot test before full rollout.
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on August 14, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of 79,000 restricted stock units (“RSUs”) and 56,525 non-qualified stock options (“NSOs”) to three newly hired non-executive employees.Additionally, the Compensation Committee granted inducement awards consisting of 65,000 RSUs and 56,000 NSOs to Yanina Grant-Huerta, our Chief Financial Officer.The foregoing inducement awards were granted as inducements material to the new employees entering into employment with Imagene in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the Company’s 2025 Equity Inducement Plan and the applicable equity award agreements.Ms. Grant-Huerta was also granted 39,000 restricted stock units under the Company’s 2025 Equity Incentive Plan.
The RSUs granted to two of the non-executive employees vest in equal annual installments over four years, subject to the grantee’s continuous service through each vesting date. The RSUs granted to Ms. Grant-Huerta and one of the non-executive employees vests over four years, with 25% of the RSUs vesting after one year and the balance of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the grantee’s continuous service through each vesting date. Each NSO has an exercise price equal to $5.84 per share, the closing price of Imagene’s common stock on August 14, 2026. The NSOs vest over four years, with 25% of the shares vesting after one year and the remaining 75% of the shares vesting in equal monthly installments over the following 36 months, subject to the grantee’s continuous service through each vesting date.
About ImageneBio, Inc.
Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company's program, olevaprubart, is a receptor targeting, nondepleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of olevaprubart in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of olevaprubart in patients with moderate-to-severe atopic dermatitis. For more information, please visit www.imagenebio.com.
What did ImageneBio (NASDAQ: IMA) announce on August 17, 2026 about stock inducement grants?
ImageneBio announced new inducement equity awards for four employees, including its CFO, granted on August 14, 2026. According to Imagene, these comprise restricted stock units and non-qualified stock options issued under its 2025 Equity Inducement Plan and 2025 Equity Incentive Plan.
How many RSUs and stock options did ImageneBio (IMA) grant as inducement awards in August 2026?
ImageneBio granted 79,000 RSUs and 56,525 NSOs to three non-executive employees and 65,000 RSUs and 56,000 NSOs to its CFO. According to Imagene, the CFO also received an additional 39,000 RSUs under the 2025 Equity Incentive Plan.
What are the vesting terms for the new ImageneBio (IMA) RSU inducement grants?
ImageneBio’s RSUs for two non-executive employees vest in equal annual installments over four years. According to Imagene, RSUs for the CFO and one non-executive employee vest 25% after one year, with the remaining 75% vesting in 12 equal quarterly installments, subject to continuous service.
What is the exercise price and vesting schedule of the new ImageneBio (IMA) stock options?
Each non-qualified stock option has an exercise price of $5.84 per share, matching ImageneBio’s August 14, 2026 closing price. According to Imagene, options vest over four years, with 25% after one year and the remaining 75% vesting in equal monthly installments.
Why did ImageneBio use Nasdaq Listing Rule 5635(c)(4) for these inducement grants?
ImageneBio stated the awards were granted as inducements material to the new employees entering employment, in accordance with Nasdaq Listing Rule 5635(c)(4). According to Imagene, the grants are issued under its 2025 Equity Inducement Plan and related equity award agreements.
Who is the key executive receiving inducement awards at ImageneBio (IMA), and what did she receive?
Chief Financial Officer Yanina Grant-Huerta received 65,000 RSUs and 56,000 NSOs as inducement awards. According to Imagene, she was also granted 39,000 additional RSUs under the 2025 Equity Incentive Plan, all subject to four-year vesting and continuous service conditions.
What clinical-stage program is ImageneBio (IMA) currently developing alongside these equity grants?
ImageneBio is developing olevaprubart, a nondepleting anti-OX40 monoclonal antibody for immune-related diseases. According to Imagene, Phase 1b/2a trials in atopic dermatitis and alopecia areata are completed, and a Phase 2b trial in moderate-to-severe atopic dermatitis is ongoing.
